Givinostat API (CAS No. 497833-27-9) is a synthetic small-molecule histone deacetylase inhibitor active pharmaceutical ingredient associated with Duchenne muscular dystrophy, neuromuscular disease, epigenetic modulation, and rare disease pharmaceutical development.
Givinostat, also known by the development code ITF2357, belongs to the histone deacetylase inhibitor class of pharmaceutical compounds.
Histone deacetylases, commonly abbreviated as HDACs, are enzymes involved in the regulation of chromatin structure, gene transcription, and multiple cellular signaling processes.
Givinostat inhibits histone deacetylase activity.
The precise mechanism by which Givinostat produces its therapeutic effect in patients with Duchenne muscular dystrophy is not fully understood.
Givinostat is associated with modulation of pathogenic processes involved in dystrophic muscle, including processes related to inflammation, muscle degeneration, fibrosis, and replacement of muscle tissue by fat.
Givinostat represents a nonsteroidal pharmaceutical approach to Duchenne muscular dystrophy treatment.
The compound is associated with pharmaceutical treatment across DMD genetic variants rather than being restricted to a specific exon-skipping-amenable mutation.
Givinostat-related pharmaceutical products are administered orally and are associated with Duchenne muscular dystrophy treatment in patients six years of age and older.
Pharmaceutical companies sourcing Givinostat API commonly evaluate assay, HPLC purity, related substances, process-related impurities, degradation products, residual solvents, water content, crystal form, polymorphic characteristics, particle size distribution, and batch-to-batch consistency.
Givinostat free base and Givinostat Hydrochloride Monohydrate should be treated as separate pharmaceutical material identities.
The approved oral pharmaceutical product uses Givinostat Hydrochloride Monohydrate.
Procurement, formulation, quality, and regulatory teams should confirm whether Givinostat free base or Givinostat Hydrochloride Monohydrate is required before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supplies Givinostat API for qualified pharmaceutical research, HDAC inhibitor development, Duchenne muscular dystrophy pharmaceutical development, rare disease research, analytical requirements, formulation development, and regulated pharmaceutical manufacturing requirements with product-specific quality documentation, pharmaceutical-grade packaging, and reliable supply-chain coordination.
Givinostat API is primarily associated with:
Givinostat-related pharmaceutical products are associated with treatment of Duchenne muscular dystrophy in patients six years of age and older.
Duchenne muscular dystrophy is a progressive neuromuscular disease associated with muscle degeneration and loss of muscle function.
Givinostat represents a histone deacetylase inhibitor pharmaceutical approach to DMD treatment.
Get Bulk Quote via WhatsApp